Brown Advisory’s Puma Biotechnology PBYI Stock Holding History

Brown Advisory’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-9,777	Closed	-$578K	–	1371
2018 Q2	$578K	Buy	9,777 +4,589	+88%	+$266K	﹤0.01%	941
2018 Q1	$353K	Buy	5,188 +277	+6%	+$20.7K	﹤0.01%	921
2017 Q4	$484K	Buy	4,911 +2,242	+84%	+$251K	﹤0.01%	884
2017 Q3	$320K	Buy	+2,669	New	+$248K	﹤0.01%	995
2015 Q2	–	Sell	-1,110	Closed	-$262K	–	902
2015 Q1	$262K	Buy	+1,110	New	+$237K	﹤0.01%	833

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Brown Advisory's PBYI Position: Q3 2018 in Review

Brown Advisory sold out of Puma Biotechnology (PBYI) in Q3 2018, closing a stake of 9,777 shares — an estimated $578K sold.

Brown Advisory first reported a position in PBYI in Q1 2015 and held it in 5 quarters. The position peaked at $578K in Q2 2018. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2018.

Brown Advisory reported no remaining Puma Biotechnology position as of Q3 2018 after selling out during the quarter.
Brown Advisory sold 9,777 Puma Biotechnology shares in Q3 2018, an estimated $578K.
Brown Advisory first reported a position in Puma Biotechnology in Q1 2015 and held it in 5 quarters.
Brown Advisory's Puma Biotechnology position peaked at $578K in Q2 2018.
156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2018.

Based on Brown Advisory's 13F filing for Q3 2018, filed 13 Nov 2018.